Preclinical validation of rilmenidine for repurposing in pancreatic ductal adenocarcinoma
Аутори
Grahovac, J.Živić, K.
Pavlović, M.
Ostojić, M.
Đurić, A.
Srdić Rajić, T.
Pavić, Aleksandar
Galun, D.
Конференцијски прилог (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
Introduction: Pancreatic ductal adenocarcinoma (PDAC) has dismal
prognosis, as there are no screening tests available, most
often is diagnosed in the metastatic phase of the disease
and is refractory to conventional, targeted and
immunotherapy. We have examined the expression and
role of the novel tumor suppressor nischarin (NISCH) in
PDAC and the effects of treatment with the agonist
rilmenidine (approved for treatment of hypertension) in
order to determine the potential of nischarin agonists for
repurposing in this deadly disease.
Извор:
Molecular oncology, 2023, 17, Supplement 1, 347-348Издавач:
- Wiley
Напомена:
- EACR 2023: Innovative Cancer Science, 12-15 June 2023, Torino, Italy
URI
https://febs.onlinelibrary.wiley.com/doi/10.1002/1878-0261.13471https://imagine.imgge.bg.ac.rs/handle/123456789/1912
Колекције
Институција/група
Institut za molekularnu genetiku i genetičko inženjerstvoTY - CONF AU - Grahovac, J. AU - Živić, K. AU - Pavlović, M. AU - Ostojić, M. AU - Đurić, A. AU - Srdić Rajić, T. AU - Pavić, Aleksandar AU - Galun, D. PY - 2023 UR - https://febs.onlinelibrary.wiley.com/doi/10.1002/1878-0261.13471 UR - https://imagine.imgge.bg.ac.rs/handle/123456789/1912 AB - Introduction: Pancreatic ductal adenocarcinoma (PDAC) has dismal prognosis, as there are no screening tests available, most often is diagnosed in the metastatic phase of the disease and is refractory to conventional, targeted and immunotherapy. We have examined the expression and role of the novel tumor suppressor nischarin (NISCH) in PDAC and the effects of treatment with the agonist rilmenidine (approved for treatment of hypertension) in order to determine the potential of nischarin agonists for repurposing in this deadly disease. PB - Wiley C3 - Molecular oncology T1 - Preclinical validation of rilmenidine for repurposing in pancreatic ductal adenocarcinoma EP - 348 IS - Supplement 1 SP - 347 VL - 17 DO - doi.org/10.1002/1878-0261.13471 ER -
@conference{ author = "Grahovac, J. and Živić, K. and Pavlović, M. and Ostojić, M. and Đurić, A. and Srdić Rajić, T. and Pavić, Aleksandar and Galun, D.", year = "2023", abstract = "Introduction: Pancreatic ductal adenocarcinoma (PDAC) has dismal prognosis, as there are no screening tests available, most often is diagnosed in the metastatic phase of the disease and is refractory to conventional, targeted and immunotherapy. We have examined the expression and role of the novel tumor suppressor nischarin (NISCH) in PDAC and the effects of treatment with the agonist rilmenidine (approved for treatment of hypertension) in order to determine the potential of nischarin agonists for repurposing in this deadly disease.", publisher = "Wiley", journal = "Molecular oncology", title = "Preclinical validation of rilmenidine for repurposing in pancreatic ductal adenocarcinoma", pages = "348-347", number = "Supplement 1", volume = "17", doi = "doi.org/10.1002/1878-0261.13471" }
Grahovac, J., Živić, K., Pavlović, M., Ostojić, M., Đurić, A., Srdić Rajić, T., Pavić, A.,& Galun, D.. (2023). Preclinical validation of rilmenidine for repurposing in pancreatic ductal adenocarcinoma. in Molecular oncology Wiley., 17(Supplement 1), 347-348. https://doi.org/doi.org/10.1002/1878-0261.13471
Grahovac J, Živić K, Pavlović M, Ostojić M, Đurić A, Srdić Rajić T, Pavić A, Galun D. Preclinical validation of rilmenidine for repurposing in pancreatic ductal adenocarcinoma. in Molecular oncology. 2023;17(Supplement 1):347-348. doi:doi.org/10.1002/1878-0261.13471 .
Grahovac, J., Živić, K., Pavlović, M., Ostojić, M., Đurić, A., Srdić Rajić, T., Pavić, Aleksandar, Galun, D., "Preclinical validation of rilmenidine for repurposing in pancreatic ductal adenocarcinoma" in Molecular oncology, 17, no. Supplement 1 (2023):347-348, https://doi.org/doi.org/10.1002/1878-0261.13471 . .